Pemetrexed + Cisplatin (or Carboplatin)
Treatment for Mesothelioma
Typical Dosage: Pemetrexed 500mg/m² IV D1 + Cisplatin 75mg/m² IV D1, every 21 days
Effectiveness
60%
Safety Score
25%
Clinical Trials
21
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Pemetrexed 500mg/m² IV D1 + Cisplatin 75mg/m² IV D1, every 21 days
Time to Effect
6-9 weeks (initial response)
Treatment Duration
4-6 cycles (3-6 months)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$8,000
Side Effect Mgmt:$7,000
Total Annual:$20,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$44,444
Cost per Remission
$400,000
Pemetrexed + Cisplatin (or Carboplatin) Outcomes
for Mesothelioma
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+45%
Remission Rate
+5%
Common Side Effects
Neutropenia
+25%
Fatigue
+40%
Nausea/Vomiting
+30%
Anorexia
+20%
Anemia
+25%
Nephrotoxicity (Cisplatin)
+15%
Active Clinical Trials
11 active trials recruiting for Pemetrexed + Cisplatin (or Carboplatin) in Mesothelioma
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
NCT06057935RECRUITINGPHASE2
64 participants
INTERVENTIONAL
Chicago, United States +12 more
Started: Sep 21, 2023
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
NCT07234058NOT YET RECRUITINGPHASE2
126 participants
INTERVENTIONAL
Aix-en-Provence, France +36 more
Started: Feb 1, 2026
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
NCT04162015ACTIVE NOT RECRUITINGPHASE1
22 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Nov 12, 2019
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
NCT05136677ACTIVE NOT RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Beijing, China +20 more
Started: Jan 25, 2022
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
NCT02535312ACTIVE NOT RECRUITINGPHASE1, PHASE2
30 participants
INTERVENTIONAL
Duarte, United States +13 more
Started: Mar 8, 2016
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
NCT06155279RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Bergamo, Italy +7 more
Started: Nov 6, 2024
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728RECRUITINGPHASE3
825 participants
INTERVENTIONAL
Phoenix, United States +177 more
Started: Nov 9, 2023
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
NCT06318286RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Nishinomiya, Japan
Started: Mar 13, 2024
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
NCT05932199RECRUITINGPHASE1, PHASE2
52 participants
INTERVENTIONAL
Durham, United States +1 more
Started: Jul 3, 2024
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
NCT00715611ACTIVE NOT RECRUITINGPHASE2
65 participants
INTERVENTIONAL
Tampa, United States +11 more
Started: Oct 11, 2008
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
NCT07131345NOT YET RECRUITINGPHASE1, PHASE2
55 participants
INTERVENTIONAL
Started: Sep 1, 2025
Completed Clinical Trials
7 completed trials for Pemetrexed + Cisplatin (or Carboplatin) in Mesothelioma
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
NCT02397928COMPLETEDPHASE2
82 participants
INTERVENTIONAL
Antwerp, Belgium +12 more
Started: Feb 1, 2015
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
NCT02899299COMPLETEDPHASE3
605 participants
INTERVENTIONAL
San Francisco, United States +108 more
Started: Nov 29, 2016
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04334759COMPLETEDPHASE3
214 participants
INTERVENTIONAL
La Jolla, United States +56 more
Started: Feb 18, 2021
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
NCT04177953COMPLETEDPHASE2
92 participants
INTERVENTIONAL
Berlin, Germany +11 more
Started: Feb 4, 2019
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
NCT00528619COMPLETEDPHASE1
96 participants
INTERVENTIONAL
Aurora, United States +2 more
Started: Nov 1, 2006
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
NCT02899195COMPLETEDPHASE2
55 participants
INTERVENTIONAL
La Jolla, United States +19 more
Started: Jun 13, 2017
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
NCT00996567COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Antwerp, Belgium +3 more
Started: Oct 1, 2009
Showing 20 of 22 total trials